ESC Premium Access

Heart failure with mid-range and preserved ejection fraction

Event: ESC CONGRESS 2017
Topic: Diastolic dysfunction
Session type: Advances in Science
Date: 27 August 2017
Time: 14:00 - 15:30

Congress Session

5 presentations in this session

State of the Art: HFmrEF - The new middle child

Speaker: Professor R. De Boer (Groningen, NL)
Thumbnail

Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction

Speaker: Doctor G. Savarese (Stockholm, SE)
Thumbnail

Prognostic relevance of the 40% left ventricular ejection fraction cut-off in chronic systolic heart failure

Speaker: Doctor A. Aimo (Pisa, IT)
Thumbnail

Prognostic relevance of preclinical diastolic dysfunction across left ventricular ejection fraction categories. The DAVID-Berg study

Speaker: Doctor M. Gori (Bergamo, IT)
Thumbnail

Should we abandon EF to stratify heart failure treatment?

Speaker: Professor S. Solomon (Boston, US)
Thumbnail

5 speakers from this session

Professor Rudolf De Boer

University Medical Centre Groningen, Groningen (Netherlands (The))
42 presentations
1 follower

Doctor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)
16 presentations
0 follower

Doctor Alberto Aimo

Sant'Anna School of Advanced Studies, Pisa (Italy)
4 presentations
0 follower

Doctor Mauro Gori

Papa Giovanni XXIII Hospital, Bergamo (Italy)
0 follower

Professor Scott Solomon

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
43 presentations
12 followers

This platform is supported by

logo Novo Nordisk